A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris

Summary

Enrollment of subjects with mild to moderate facial acne. Efficacy was assessed by using an Investigator's Global Assessment scale (IGA 5 point scale) and by counting the number of inflammatory and non-inflammatory lesions on the face at Baseline and Weeks 4, 8, and 12. Safety assessments included the investigator's assessment of local cutaneous tolerance of the treated skin (dryness, non-lesional erythema, peeling, stinging, burning, and itching, vital signs, and adverse events (AEs).

Timeline

Start

2017-07-31

Primary completion

2018-04-19

Completion

2018-04-19

Drugs

Indications